Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05409092 · ClinicalTrials.gov registry record · NA
Astaxanthin, Exercise Inflammation, Skin Health
A NA study, sponsored by Appalachian State University.
- Completed
- Registry status
- NA
- Development phase
- 22
- Enrollment target
NCT05409092: Completed NA study, sponsored by Appalachian State University.
NCT05409092 is a NA study that has completed, run by Appalachian State University. The registered enrollment target is 22 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05409092, a NA study, has completed, sponsored by Appalachian State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
Study Summary
Vigorous exercise can stress the body. Consuming special types of diet supplements may help the body recover better from exercise. This includes a bright red supplement called astaxanthin that is found in certain algae and causes the pink-red color in salmon. Astaxanthin is an antioxidant and may protect cells from damage and improve the way the immune system functions. The main purpose of this study is to determine if 4 weeks of consuming astaxanthin improves recovery from 2.25 hours of intensive running on a treadmill. This study will also measure whether or not astaxanthin supplementation improves skin health
Primary Outcome
Plasma concentrations of arachadonic acid oxidized derivatives from LC-MS-MS analysis
Interventions
- DIETARY_SUPPLEMENT Astaxanthin
- DIETARY_SUPPLEMENT Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2022-01-19 |
| Est. Completion | 2022-12-30 |
| Phase | NA |
What the finished NCT05409092 record still lists
NCT05409092 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Astaxanthin is the first listed.
NCT05409092 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05409092 about?
NCT05409092 is a clinical study titled "Astaxanthin, Exercise Inflammation, Skin Health". Vigorous exercise can stress the body. Consuming special types of diet supplements may help the body recover better from exercise. This includes a bright red supplement called astaxanthin that is found in certain algae and causes the pink-red color in salmon. Astaxanthin is an antioxidant and may pr...
What is the current status of trial NCT05409092?
This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2022-01-19. Estimated completion is 2022-12-30.
What interventions are being tested in trial NCT05409092?
The interventions under investigation include: Astaxanthin (DIETARY_SUPPLEMENT), Placebo (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05409092?
This trial is sponsored by Appalachian State University, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05409092's enrollment target sits among peer trials
22 1756th of 2000 higher than 239 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI